Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 7008.50
NRIFF's Cash to Debt is ranked higher than
66% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. NRIFF: 7008.50 )
Ranked among companies with meaningful Cash to Debt only.
NRIFF' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 6.42 Max: No Debt
Current: 7008.5
Equity to Asset 0.78
NRIFF's Equity to Asset is ranked higher than
73% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NRIFF: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
NRIFF' s Equity to Asset Range Over the Past 10 Years
Min: -0.42  Med: 0.76 Max: 0.99
Current: 0.78
-0.42
0.99
F-Score: 2
Z-Score: -0.85
M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -20.58
NRIFF's Operating margin (%) is ranked lower than
82% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.49 vs. NRIFF: -20.58 )
Ranked among companies with meaningful Operating margin (%) only.
NRIFF' s Operating margin (%) Range Over the Past 10 Years
Min: -331.76  Med: -54.77 Max: 170.76
Current: -20.58
-331.76
170.76
Net-margin (%) -32.87
NRIFF's Net-margin (%) is ranked lower than
84% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.03 vs. NRIFF: -32.87 )
Ranked among companies with meaningful Net-margin (%) only.
NRIFF' s Net-margin (%) Range Over the Past 10 Years
Min: -306.38  Med: -55.70 Max: 295.55
Current: -32.87
-306.38
295.55
ROE (%) -18.32
NRIFF's ROE (%) is ranked lower than
79% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. NRIFF: -18.32 )
Ranked among companies with meaningful ROE (%) only.
NRIFF' s ROE (%) Range Over the Past 10 Years
Min: -978.57  Med: -38.05 Max: 113.73
Current: -18.32
-978.57
113.73
ROA (%) -15.67
NRIFF's ROA (%) is ranked lower than
80% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. NRIFF: -15.67 )
Ranked among companies with meaningful ROA (%) only.
NRIFF' s ROA (%) Range Over the Past 10 Years
Min: -92.28  Med: -29.80 Max: 88.96
Current: -15.67
-92.28
88.96
ROC (Joel Greenblatt) (%) -275.13
NRIFF's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.14 vs. NRIFF: -275.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NRIFF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -580.94  Med: -411.11 Max: 3057.7
Current: -275.13
-580.94
3057.7
Revenue Growth (3Y)(%) -11.60
NRIFF's Revenue Growth (3Y)(%) is ranked lower than
85% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NRIFF: -11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NRIFF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: -1.15 Max: 25.5
Current: -11.6
-30.1
25.5
EBITDA Growth (3Y)(%) -24.00
NRIFF's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NRIFF: -24.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NRIFF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.2  Med: -16.80 Max: 49.7
Current: -24
-40.2
49.7
EPS Growth (3Y)(%) -25.20
NRIFF's EPS Growth (3Y)(%) is ranked lower than
84% of the 498 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. NRIFF: -25.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NRIFF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.6  Med: -20.60 Max: 50.4
Current: -25.2
-41.6
50.4
» NRIFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NRIFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XKRX:009300, BOM:590006, XKRX:018680, AMEX:PVCT, XKRX:047920, XKRX:053950 » details
Traded in other countries:NRI.Canada, 23N.Germany,
Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.

Nuvo Research, Inc. was incorporated on August 22, 1983 under the laws of the Province of Ontario. The Company is a publicly traded Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group. The TPT Group has four commercialized products, a pipeline of products at various stages of development focusing on the following therapeutic areas: pain, dermatology, central nervous system (CNS) and endocrinology and four topical and transdermal drug delivery (TTDD) platforms. The Immunology Group has two commercialized products, a development program for the treatment of allergic rhinitis and a potential immune system modulation platform. The Company has four commercialized products: Pennsaid, Pennsaid 2%, the heated lidocaine/tetracaine patch (HLT Patch, formerly known as Synera) and Pliaglis. The Company is building a portfolio of products for the treatment of pain through internal research and development (R&D) and by in-licensing and acquisition. The Company is also involved in R&D activities with WF10, a chlorite-based immune modulating drug, through Nuvo Research AG.

Ratios

vs
industry
vs
history
Forward P/E 7.42
NRIFF's Forward P/E is ranked higher than
85% of the 73 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.02 vs. NRIFF: 7.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.41
NRIFF's P/B is ranked lower than
72% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. NRIFF: 4.41 )
Ranked among companies with meaningful P/B only.
NRIFF' s P/B Range Over the Past 10 Years
Min: 0.61  Med: 2.03 Max: 41.69
Current: 4.41
0.61
41.69
P/S 2.95
NRIFF's P/S is ranked lower than
54% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. NRIFF: 2.95 )
Ranked among companies with meaningful P/S only.
NRIFF' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 3.19 Max: 32.38
Current: 2.95
0.77
32.38
Current Ratio 4.26
NRIFF's Current Ratio is ranked higher than
72% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. NRIFF: 4.26 )
Ranked among companies with meaningful Current Ratio only.
NRIFF' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 3.66 Max: 25.02
Current: 4.26
0.14
25.02
Quick Ratio 3.76
NRIFF's Quick Ratio is ranked higher than
74% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. NRIFF: 3.76 )
Ranked among companies with meaningful Quick Ratio only.
NRIFF' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 3.29 Max: 23.62
Current: 3.76
0.05
23.62
Days Inventory 68.76
NRIFF's Days Inventory is ranked higher than
76% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.44 vs. NRIFF: 68.76 )
Ranked among companies with meaningful Days Inventory only.
NRIFF' s Days Inventory Range Over the Past 10 Years
Min: 75.26  Med: 88.19 Max: 181.84
Current: 68.76
75.26
181.84
Days Sales Outstanding 48.57
NRIFF's Days Sales Outstanding is ranked higher than
74% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. NRIFF: 48.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRIFF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.84  Med: 83.12 Max: 94.58
Current: 48.57
55.84
94.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.28
NRIFF's Price/Net Cash is ranked higher than
60% of the 220 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.52 vs. NRIFF: 8.28 )
Ranked among companies with meaningful Price/Net Cash only.
NRIFF' s Price/Net Cash Range Over the Past 10 Years
Min: 0.9  Med: 7.98 Max: 949.49
Current: 8.28
0.9
949.49
Price/Net Current Asset Value 4.72
NRIFF's Price/Net Current Asset Value is ranked higher than
67% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.95 vs. NRIFF: 4.72 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NRIFF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.84  Med: 4.60 Max: 4030
Current: 4.72
0.84
4030
Price/Tangible Book 4.43
NRIFF's Price/Tangible Book is ranked lower than
61% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. NRIFF: 4.43 )
Ranked among companies with meaningful Price/Tangible Book only.
NRIFF' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.82  Med: 4.01 Max: 1597.5
Current: 4.43
0.82
1597.5
Price/Median PS Value 0.92
NRIFF's Price/Median PS Value is ranked higher than
66% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.12 vs. NRIFF: 0.92 )
Ranked among companies with meaningful Price/Median PS Value only.
NRIFF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.48 Max: 124.61
Current: 0.92
0.28
124.61
Earnings Yield (Greenblatt) (%) -7.17
NRIFF's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. NRIFF: -7.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NRIFF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.17  Med: 28.60 Max: 726.5
Current: -7.17
-7.17
726.5

More Statistics

Revenue (TTM) (Mil) $18.58
EPS (TTM) $ -0.59
Beta-0.43
Short Percentage of Float0.00%
52-Week Range $3.67 - 5.60
Shares Outstanding (Mil)11.49

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 23 25
EPS ($) 0.58 0.66
EPS without NRI ($) 0.58 0.66
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NRIFF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results May 11 2016
Nuvo Research reports 1Q loss May 11 2016
Nuvo Research reports 1Q loss May 11 2016
Nuvo Pharmaceuticals™ Inc. announces appointment of Vice President, Business Development Apr 04 2016
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies Mar 01 2016
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies Mar 01 2016
Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10™ for the Treatment of Allergic... Dec 21 2015
Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10™ for the Treatment of Allergic... Dec 21 2015
Nuvo Research reports 3Q loss Nov 10 2015
Nuvo Research reports 3Q loss Nov 10 2015
NRI.TO: Nuvo Research Intends to Split Into Two Publicly Traded Companies Sep 16 2015
Nuvo Research® Announces Intention to Split Into Two Publicly Traded Companies Sep 15 2015
NRI.TO: Update on Second Quarter 2015 Financials Aug 27 2015
Nuvo Research® Announces U.S. Patent for Topical Foamed Formulations that Include DMSO Aug 20 2015
Nuvo Research® Announces Grant of United States Patent for Topical Onychomycosis Formulation Aug 11 2015
Nuvo Research® Announces 2015 Second Quarter Results Aug 05 2015
Nuvo Research® Provides Update on International Licensing of Pennsaid® 2% Jun 24 2015
Nuvo Research® Receives Health Canada Approval to Conduct New WF10™ Phase 2 Trial Jun 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)